In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
PCI Biotech Holding ASA's net current asset value per share for the quarter that ended in Jun. 2025 was kr0.31.
The historical rank and industry rank for PCI Biotech Holding ASA's Net Current Asset Value or its related term are showing as below:
OSL:PCIB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.23 Med: 4.89 Max: 69.28
Current: 0.23
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of PCI Biotech Holding ASA was 69.28. The lowest was 0.23. And the median was 4.89.
OSL:PCIB's Price-to-Net-Current-Asset-Value is not ranked
in the Biotechnology industry.
Industry Median: 4.955
vs OSL:PCIB: 0.23
PCI Biotech Holding ASA (OSL:PCIB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
PCI Biotech Holding ASA Net Current Asset Value Related Terms
PCI Biotech Holding ASA Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for PCI Biotech Holding ASA's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA Net Current Asset Value Chart
OSL:PCIB vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, PCI Biotech Holding ASA's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of kr0.31 mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Net Current Asset Value of kr0.31 as of Jun. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PCI Biotech Holding ASA and its competitors. This is 94% below median its historical median of 4.89. Over the past decade, PCI Biotech Holding ASA's Net Current Asset Value has ranged from 0.23 to 69.28.
Is PCI Biotech Holding ASA's Net Current Asset Value too high?
PCI Biotech Holding ASA's current Net Current Asset Value of kr0.31 is 94% below median its 10-year median of 4.89. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 69.28. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Net Current Asset Value compare to VRTX and REGN?
PCI Biotech Holding ASA's Net Current Asset Value of kr0.31 can be compared against companies in the Biotechnology industry. The industry median Net Current Asset Value is 4.96. Historically, PCI Biotech Holding ASA's own Net Current Asset Value has ranged from 0.23 to 69.28 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current Net Current Asset Value is kr0.31, which is 94% below median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Net Current Asset Value of kr0.31. The current Net Current Asset Value is kr0.31, which is 94% below median its 10-year median of 4.89. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Net Current Asset Value is kr0.31 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score
Get the complete analysis for OSL:PCIB
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PCIB has been successfully added to your 
